SCHEMBL4352302

SCHEMBL4352302

O=C1N=C(N2CCOCC2)SC1=CCCc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 12/20 0.60
RAB9A P51151 5/20 0.60
MEN1 O00255 5/20 0.60
KMT2A Q03164 5/20 0.60
NPC1 O15118 3/20 0.60
CYP1A2 P05177 2/20 0.60
CYP2C19 P33261 2/20 0.60
ALDH1A1 P00352 7/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
HCRTR1 O43613 1/20 0.56
GAA P10253 2/20 0.51
KDM4E B2RXH2 1/20 0.51
HPGD P15428 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
POLB P06746 3/20 0.49
LMNA P02545 1/20 0.49
HTT P42858 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4352300 1.00 MAPT (0.60) MAPTRAB9AMEN1KMT2ANPC1
SCHEMBL4346511 0.89 MAPT (0.63) MAPTRAB9AMEN1KMT2ANPC1
Hydrochloric Acid SCHEMBL4346483 0.88 MAPT (0.62) MAPTRAB9AMEN1KMT2ANPC1
SCHEMBL4347979 0.80 RECQL (0.54) MAPTRAB9AMEN1KMT2ANPC1
SCHEMBL4347983 0.80 RECQL (0.54) MAPTRAB9AMEN1KMT2ANPC1
SCHEMBL4354253 0.79 ALDH1A1 (0.78) MAPTRAB9AMEN1KMT2ANPC1
SCHEMBL4354258 0.79 ALDH1A1 (0.78) MAPTRAB9AMEN1KMT2ANPC1
SCHEMBL4352058 0.78 MAPT (0.56) MAPTRAB9AMEN1KMT2ANPC1
SCHEMBL4352056 0.78 MAPT (0.56) MAPTRAB9AMEN1KMT2ANPC1
Bromide SCHEMBL4352442 0.78 ALDH1A1 (0.76) MAPTRAB9AMEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP claimed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US claimed
EP-1890695-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2008-02-27 EP claimed
WO-2006122777-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2006-11-23 WO claimed
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP disclosed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US disclosed
EP-1890695-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2008-02-27 EP disclosed
WO-2006122777-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs ABCB1, ABCG2, SLC5A2 MAPT 1470/4885RAB9A 3151/4885MEN1 1725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.